28 Mar 2019

CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis 

Read More
19 Mar 2019

Transparency notification BlackRock, Inc.

Read More
13 Mar 2019

Transparency notification UCB SA/NV

Read More
11 Mar 2019

Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)

Read More
28 Feb 2019

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study 

Read More
28 Feb 2019

New Data Affirms Strength of UCB Immuno-Dermatology Portfolio

Read More
27 Feb 2019

UCB Full Year Report 2018: 2018 marks the fifth consecutive year of profitable growth, intensifying investment in UCB’s strong pipeline

Read More
15 Feb 2019

UCB builds on its R&D footprint to form a research satellite facility within King’s College London

Read More
10 Feb 2019

UCB and Epilepsy Society announce pioneering UK Genomics R&D collaboration 

Read More
30 Jan 2019

Transparency notification BlackRock, Inc.

Read More
Subscribe to